MedTrace Logo

Efficacy of Ascorbic Acid for Prevention of Colistin-Associated Nephrotoxicity

NCT01501968 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2011-12-30

No results posted yet for this study

Summary

Ascorbic acid (Vitamin C) could protect renal toxicity from colistin.

Conditions

  • Drug Safety

Interventions

DRUG

Colistin

Colistimethate sodium 2.5-5mg/kg iv per day

DRUG

Colistin + Ascorbic acid

Colistimethate sodium 2.5-5mg/kg iv per day and ascorbic acid 2 grams iv q 12 hours

Sponsors & Collaborators

  • Siriraj Hospital

    collaborator OTHER

  • Mahidol University

    lead OTHER

Principal Investigators

  • Visanu Thamlikitkul, MD · Siriraj Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01501968 on ClinicalTrials.gov